GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » Cyclically Adjusted FCF per Share

Dendreon (FRA:DNR) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Dendreon Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Dendreon's adjusted free cash flow per share for the three months ended in Sep. 2014 was €-0.118. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Sep. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-17), Dendreon's current stock price is €0.13. Dendreon's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2014 was €0.00. Dendreon's Cyclically Adjusted Price-to-FCF of today is .


Dendreon Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Dendreon's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dendreon Cyclically Adjusted FCF per Share Chart

Dendreon Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dendreon Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Mar15
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dendreon's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Dendreon's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dendreon's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dendreon's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Dendreon's Cyclically Adjusted Price-to-FCF falls into.



Dendreon Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dendreon's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2014 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-0.118/100.4278*100.4278
=-0.118

Current CPI (Sep. 2014) = 100.4278.

Dendreon Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200412 -0.219 80.290 -0.274
200503 -0.273 81.555 -0.336
200506 -0.269 82.062 -0.329
200509 -0.287 83.876 -0.344
200512 -0.205 83.032 -0.248
200603 -0.338 84.298 -0.403
200606 -0.352 85.606 -0.413
200609 -0.204 85.606 -0.239
200612 -0.141 85.142 -0.166
200703 -0.291 86.640 -0.337
200706 -0.199 87.906 -0.227
200709 -0.122 87.964 -0.139
200712 -0.151 88.616 -0.171
200803 -0.150 90.090 -0.167
200806 -0.119 92.320 -0.129
200809 -0.149 92.307 -0.162
200812 -0.141 88.697 -0.160
200903 -0.138 89.744 -0.154
200906 -0.255 91.003 -0.281
200909 -0.148 91.120 -0.163
200912 -0.422 91.111 -0.465
201003 -0.433 91.821 -0.474
201006 -0.689 91.962 -0.752
201009 -0.534 92.162 -0.582
201012 -0.617 92.474 -0.670
201103 -0.505 94.283 -0.538
201106 -0.528 95.235 -0.557
201109 -0.521 95.727 -0.547
201112 0.265 95.213 0.280
201203 -0.294 96.783 -0.305
201206 -0.261 96.819 -0.271
201209 -0.328 97.633 -0.337
201212 -0.297 96.871 -0.308
201303 -0.454 98.209 -0.464
201306 -0.276 98.518 -0.281
201309 -0.225 98.790 -0.229
201312 -0.157 98.326 -0.160
201403 -0.132 99.695 -0.133
201406 -0.022 100.560 -0.022
201409 -0.118 100.428 -0.118

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Dendreon  (FRA:DNR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Dendreon Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Dendreon's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dendreon (FRA:DNR) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Dendreon (FRA:DNR) Headlines

No Headlines